OOIR: Observatory of International Research

Papers

(The H4-Index of Nature Medicine is 183. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Temporal dynamics in viral shedding and transmissibility of COVID-19	3086
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection	3040
Post-acute COVID-19 syndrome	2922
Antibody responses to SARS-CoV-2 in patients with COVID-19	2304
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections	2178
Extrapulmonary manifestations of COVID-19	2154
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes	2045
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19	1978
A global survey of potential acceptance of a COVID-19 vaccine	1789
An inflammatory cytokine signature predicts COVID-19 severity and survival	1761
Respiratory virus shedding in exhaled breath and efficacy of face masks	1593
Attributes and predictors of long COVID	1548
A serological assay to detect SARS-CoV-2 seroconversion in humans	1512
Age-dependent effects in the transmission and control of COVID-19 epidemics	1271
A single-cell atlas of the peripheral immune response in patients with severe COVID-19	1212
Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy	1209
Real-time tracking of self-reported symptoms to predict potential COVID-19	1095
Long-term cardiovascular outcomes of COVID-19	1017
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma	817
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection	810
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies	761
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers	715
A dynamic COVID-19 immune signature includes associations with poor prognosis	711
Artificial intelligence–enabled rapid diagnosis of patients with COVID-19	676
Digital technologies in the public-health response to COVID-19	673

COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries	650
AI in health and medicine	648
Seasonal coronavirus protective immunity is short-lasting	584
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies	581
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation	527
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies	521
Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries	519
SARS-CoV-2 infection of the oral cavity and saliva	503
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma	484
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera	483
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2	481
Immune determinants of COVID-19 disease presentation and severity	477
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals	469
Clustering and superspreading potential of SARS-CoV-2 infections in Hong Kong	466
Determinants of COVID-19 disease severity in patients with cancer	464
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial	448
Targeting metastatic cancer	446
Long COVID after breakthrough SARS-CoV-2 infection	446
Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda	441
Single-cell multi-omics analysis of the immune response in COVID-19	440
Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination	440
Looking beyond COVID-19 vaccine phase 3 trials	438
Long COVID in a prospective cohort of home-isolated patients	434
Understanding COVID-19 vaccine hesitancy	423
Infection of bat and human intestinal organoids by SARS-CoV-2	422
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study	415
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein	412
Human postprandial responses to food and potential for precision nutrition	411
Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus	410
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa	407
Symptoms and risk factors for long COVID in non-hospitalized adults	403
Biomarkers for neurodegenerative diseases	391
Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine	388
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK	382
Intratumoral heterogeneity in cancer progression and response to immunotherapy	379
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection	371
A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors	369
Human–computer collaboration for skin cancer recognition	368
If the world fails to protect the economy, COVID-19 will damage health not just now but also in the future	365
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer	357
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes	355
Deep learning in histopathology: the path to the clinic	355
Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy	353
Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants	352
Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19	350
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial	349
A deep learning system for differential diagnosis of skin diseases	348
Four distinct trajectories of tau deposition identified in Alzheimer’s disease	348
Toward personalized treatment approaches for non-small-cell lung cancer	341
Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension	340

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination	337
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study	336
Disease and healthcare burden of COVID-19 in the United States	334
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial	333
Partial recovery of visual function in a blind patient after optogenetic therapy	331
A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer	331
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial	330
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis	329
Brown adipose tissue is associated with cardiometabolic health	328
Rapid pathogen detection by metagenomic next-generation sequencing of infected body fluids	325
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar	322
Modeling COVID-19 scenarios for the United States	321
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China	319
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas	318
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar	317
Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer	316
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant	315
Sixteen novel lineages of SARS-CoV-2 in South Africa	313
Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination	306
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis	304
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection	304
Wearable sensor data and self-reported symptoms for COVID-19 detection	303
Federated learning for predicting clinical outcomes in patients with COVID-19	297
Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination	296
The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial	295
SARS-CoV-2 variants of concern are emerging in India	292
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant	291
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors	288
Single-cell transcriptomic atlas of the human endometrium during the menstrual cycle	288
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial	285
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial	279
Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells	279
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England	278
Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries	276
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial	271
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers	270
Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination	267
Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome sequencing and agent-based modeling	263
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters	263
COVID-19 in Amazonas, Brazil, was driven by the persistence of endemic lineages and P.1 emergence	262
Cellular senescence and senolytics: the path to the clinic	261
Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States	261
A single-cell landscape of high-grade serous ovarian cancer	260
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial	259
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults	257
Minimum information about clinical artificial intelligence modeling: the MI-CLAIM checklist	256
Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals	256
Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease	254
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus	251
Large language models in medicine	248
Acute and postacute sequelae associated with SARS-CoV-2 reinfection	245
Targeting the HIF2–VEGF axis in renal cell carcinoma	244
Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics	244
Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma	244
Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands	242
Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial	241
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade	241
Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI extension	239
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses	239
Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection	238
Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection	238
Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster	236
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom	235
A stochastic agent-based model of the SARS-CoV-2 epidemic in France	235
Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies	230
Unexplained post-acute infection syndromes	230
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin	229
Microglial activation and tau propagate jointly across Braak stages	228
Caring for patients with cancer in the COVID-19 era	227
Long-term neurologic outcomes of COVID-19	225
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures	225
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer	224
How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals	223
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy	220
Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps	214
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern	210
Vaccine development for emerging infectious diseases	210
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies	208
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)	208
Closed-loop neuromodulation in an individual with treatment-resistant depression	207

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade	205
A guide to immunotherapy for COVID-19	205
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring	204
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial	203
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19	202
The distribution of cellular turnover in the human body	201
Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California	200
Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma	200
First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland	199
Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes	199
Underdiagnosis bias of artificial intelligence algorithms applied to chest radiographs in under-served patient populations	198
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial	197
Multimodal biomedical AI	196
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial	195
IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies	195
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results	195
A roadmap to increase diversity in genomic studies	194
Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2	194
Crowding and the shape of COVID-19 epidemics	189
A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity	189
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models	189
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma	188
Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer	188
Articular cartilage regeneration by activated skeletal stem cells	188
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma	187
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma	186
Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study	184
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial	183
Robust breast cancer detection in mammography and digital breast tomosynthesis using an annotation-efficient deep learning approach	183